AstraZeneca Plc’s coronavirus vaccine fared better than expected in a U.S. clinical trial, providing reassurance about its safety and efficacy as the drugmaker prepares to seek clearance from the Food and Drug Administration.

The shot developed with the University of Oxford was 79% effective in preventing Covid-19, the company said Monday. All those immunized were protected from severe disease and death in a study of more than 30,000 volunteers. An independent monitoring board found no safety concerns.

The findings should bolster confidence in the vaccine after confusion over its efficacy and the best dosing regimen slowed take-up. The product is at the center of a supply showdown with the European Union just days after concerns about blood clots prompted a dozen member states to suspend immunizations. Even after the European Medicines Agency declared it safe last Thursday, not all EU countries have resumed vaccinations.

“Seeing this data I hope gives others increased confidence that this is a very effective and safe vaccine,” Mene Pangalos, the drugmaker’s executive vice president for biopharmaceuticals research, said on a media call. “We’ve never had any doubt.”

Subscribe to our YouTube channel: [ Ссылка ]

Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.

To watch complete coverage on Bloomberg Quicktake 24/7, visit [ Ссылка ], or watch on Apple TV, Roku, Samsung Smart TV, Fire TV and Android TV on the Bloomberg app.

Have a story to tell? Fill out this survey for a chance to have it featured on Bloomberg Quicktake: [ Ссылка ]

Connect with us on…
YouTube: [ Ссылка ]
Breaking News on YouTube: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]

свернуть